基于机器学习的未破裂颅内动脉瘤术前预测分析:一项初步研究
本研究基于前瞻性登记数据,开发并内部验证机器学习模型,预测未破裂颅内动脉瘤显微外科术后出院时神经功能结局、新发神经功能缺损及并发症。纳入156例患者,出院时不良神经功能结局(mRS≥3)12例(7.7%),新发神经功能缺损10例(6.4%),任何并发症20例(12.8%)。内部验证队列AUC为0.63-0.77,准确度0.78-0.91,表明机器学习用于早期临床终点预测可行。
要点
- 机器学习模型可预测未破裂颅内动脉瘤显微术后早期临床终点。
- 内部验证AUC 0.63-0.77,准确度0.78-0.91。
- 出院时不良神经功能结局(mRS≥3)发生率为7.7%。
核心结论
- 机器学习能够预测未破裂颅内动脉瘤显微外科术后的早期临床终点。
- 本初步研究为开发外部验证的多中心临床预测模型奠定了基础。
研究设计与样本
- 基于前瞻性登记数据开发并内部验证机器学习模型,预测出院时神经功能结局、新发神经功能缺损及任何并发症。
- 纳入156例未破裂颅内动脉瘤患者(26.3%男性;平均[SD]年龄51.7[11.0]岁),其中37例(24%)治疗多发动脉瘤,39例(25%)治疗复杂动脉瘤。
- 输入变量包括年龄、性别、动脉瘤复杂性、直径、位置、数量、既往治疗、既往蛛网膜下腔出血、抗凝、抗血小板、高血压、显微外科技术与入路及多种未破裂动脉瘤评分系统(PHASES、ELAPSS、UIATS)。
- 良好神经功能结局定义为改良Rankin量表(mRS)0-2分;并发症按Clavien-Dindo分级(CDG)记录术后任何不良事件(手术相关与非手术相关)。
主要发现
- 出院时不良神经功能结局(mRS≥3)见于12例患者(7.7%)。
- 新发神经功能缺损见于10例患者(6.4%)。
- 任何类型并发症发生于20例患者(12.8%)。
- 内部验证队列的曲线下面积(AUC)为0.63-0.77,准确度为0.78-0.91。
关键数值与推荐
- 良好神经功能结局定义为出院时mRS 0-2分。
- 并发症按Clavien-Dindo分级记录术后任何不良事件(手术相关与非手术相关)。
- 模型输入变量包括PHASES、ELAPSS、UIATS等未破裂动脉瘤评分系统。
临床怎么用
- 机器学习模型可用于未破裂颅内动脉瘤显微外科术前个体化预测早期临床终点。
- 预测结果或有助于术前风险评估与决策,但需外部验证后方可用于临床。
局限性
- 本研究为初步研究,样本量有限(156例),仅进行内部验证。
- 模型预测性能中等(AUC 0.63-0.77),需多中心外部验证确认泛化能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The decision to treat unruptured intracranial aneurysms (UIAs) or not is complex and requires balancing of risk factors and scores. Machine learning (ML) algorithms have previously been effective at generating highly accurate and comprehensive individualized preoperative predictive analytics in transsphenoidal pituitary and open tumor surgery. In this pilot study, we evaluate whether ML-based prediction of clinical endpoints is feasible for microsurgical management of UIAs. METHODS: Based on data from a prospective registry, we developed and internally validated ML models to predict neurological outcome at discharge, as well as presence of new neurological deficits and any complication at discharge. Favorable neurological outcome was defined as modified Rankin scale (mRS) 0 to 2. According to the Clavien-Dindo grading (CDG), every adverse event during the post-operative course (surgery and not surgery related) is recorded as a complication. Input variables included age; gender; aneurysm complexity, diameter, location, number, and prior treatment; prior subarachnoid hemorrhage (SAH); presence of anticoagulation, antiplatelet therapy, and hypertension; microsurgical technique and approach; and various unruptured aneurysm scoring systems (PHASES, ELAPSS, UIATS). RESULTS: We included 156 patients (26.3% male; mean [SD] age, 51.7 [11.0] years) with UIAs: 37 (24%) of them were treated for multiple aneurysm and 39 (25%) were treated for a complex aneurysm. Poor neurological outcome (mRS ≥ 3) was seen in 12 patients (7.7%) at discharge. New neurological deficits were seen in 10 (6.4%), and any kind of complication occurred in 20 (12.8%) patients. In the internal validation cohort, area under the curve (AUC) and accuracy values of 0.63-0.77 and 0.78-0.91 were observed, respectively. CONCLUSIONS: Application of ML enables prediction of early clinical endpoints after microsurgery for UIAs. Our pilot study lays the groundwork for development of an externally validated multicenter clinical prediction model.
引用
- Staartjes VE, Sebök M, Blum PG, et al. Development of machine learning-based preoperative predictive analytics for unruptured intracranial aneurysm surgery: a pilot study. Acta Neurochir (Wien). 2020. PMID: 32358656. doi:10.1007/s00701-020-04355-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。